Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program
The Medicare GLP-1 Bridge program will provide access to Lilly's obesity treatments, Foundayo and Zepbound, for eligible Medicare Part D patients starting July 1.
Asset / Drug
Drug and asset intelligence for Foundayo with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
GLP-1 Agonists
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.